Arovella Therapeutics: Notice of Annual General Meeting/Proxy Form
Filed with ASX · · 26 pages · English
Arovella Therapeutics Limited on 6ix
In the deck
Earlier from Arovella Therapeutics
- The path to first patient dosing
- 2026 ESG Report
- Notification of 2026 AGM Date
- Clinical manufacturing batch released, first site activated
- Corporate Governance Statement
Later from Arovella Therapeutics
- Cell and Gene Innovation Spotlight Presentation
- Second Clinical Batch Released for Immediate Patient Use
- Arovella receives R&D tax rebate of $4.03 million
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patient Dosed with ALA-101
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics